Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 15 years of Receivables - Net data on file, last reported at $15.7 million in Q1 2026.

• Quarterly Receivables - Net rose 563.21% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 563.21% YoY) and the FY2025 annual result came in at $6.8 million, changed N/A from the prior year.
• Receivables - Net slipped to $15.7 million in Q1 2026, from $218.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $218.4 million in Q4 2025 to a low of $239000.0 in Q2 2022.
• A 5-year average of $30.8 million and a median of $4.7 million in 2024 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 26278.67% in 2022, down 86.25% in 2022.
• Tracing ARWR's Receivables - Net over 5 years: stood at $39.6 million in 2022, then tumbled by 96.11% to $1.5 million in 2023, then soared by 62.44% to $2.5 million in 2024, then jumped by 8634.16% to $218.4 million in 2025, then slumped by 92.82% to $15.7 million in 2026.
• The last three Receivables - Net figures came in at $15.7 million (Q1 2026), $218.4 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.